全文获取类型
收费全文 | 1671篇 |
免费 | 142篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 112篇 |
儿科学 | 87篇 |
妇产科学 | 11篇 |
基础医学 | 255篇 |
口腔科学 | 24篇 |
临床医学 | 142篇 |
内科学 | 351篇 |
皮肤病学 | 10篇 |
神经病学 | 111篇 |
特种医学 | 159篇 |
外科学 | 140篇 |
综合类 | 10篇 |
预防医学 | 165篇 |
眼科学 | 10篇 |
药学 | 122篇 |
中国医学 | 2篇 |
肿瘤学 | 110篇 |
出版年
2023年 | 5篇 |
2022年 | 7篇 |
2021年 | 19篇 |
2020年 | 15篇 |
2019年 | 14篇 |
2018年 | 20篇 |
2017年 | 22篇 |
2016年 | 25篇 |
2015年 | 30篇 |
2014年 | 51篇 |
2013年 | 56篇 |
2012年 | 72篇 |
2011年 | 80篇 |
2010年 | 38篇 |
2009年 | 55篇 |
2008年 | 72篇 |
2007年 | 66篇 |
2006年 | 73篇 |
2005年 | 87篇 |
2004年 | 70篇 |
2003年 | 77篇 |
2002年 | 80篇 |
2001年 | 60篇 |
2000年 | 57篇 |
1999年 | 57篇 |
1998年 | 57篇 |
1997年 | 69篇 |
1996年 | 50篇 |
1995年 | 46篇 |
1994年 | 40篇 |
1993年 | 32篇 |
1992年 | 34篇 |
1991年 | 25篇 |
1990年 | 13篇 |
1989年 | 33篇 |
1988年 | 29篇 |
1987年 | 26篇 |
1986年 | 31篇 |
1985年 | 26篇 |
1984年 | 13篇 |
1983年 | 10篇 |
1982年 | 13篇 |
1981年 | 7篇 |
1980年 | 11篇 |
1978年 | 6篇 |
1977年 | 8篇 |
1976年 | 6篇 |
1975年 | 6篇 |
1971年 | 4篇 |
1968年 | 4篇 |
排序方式: 共有1821条查询结果,搜索用时 17 毫秒
1.
Intracranial circulation: pulse-sequence considerations in three- dimensional (volume) MR angiography 总被引:2,自引:0,他引:2
The technique and feasibility of magnetic resonance (MR) angiography of intracranial vessels were studied in 35 healthy volunteers. Variations in image orientation, repetition time (TR), and flip angle were evaluated to determine their effects on flow-related enhancement. Gradient modifications--including echo time (TE), motion compensation, bandwidth, and field of view--were also studied in an effort to reduce motion-induced phase shifts. Results indicated that a FISP (fast imaging with steady precession) sequence with a TR of 50 msec, TE of 15 msec, velocity compensation in the read and section-select directions, acceleration compensation in the read direction, anisotropic volume, and a 1.25-mm partition thickness produced three-dimensional angiographic MR images that were accurate and reproducible in the depiction of the major intracranial vessels. Difficulties with field of view, persistent signal void secondary to higher-order motion, and spatial resolution remain major problems requiring additional study. 相似文献
2.
Paediatric dacryocystorhinostomy 总被引:1,自引:0,他引:1
KN Hakin FRCS FRCOphth TJ Sullivan FRACO FRACS A Sharma FCOphth † RAN Welham FRCS FCOphth † 《Clinical & experimental ophthalmology》1994,22(4):231-235
Of 258 cases of dacryocystorhinostomy performed on children in the period September 1981 to September 1991, 130 were for simple, unresolved congenital nasolacrimal duct obstruction. Other indications for surgery included punctal agenesis, lacrimal fistula, post-traumatic and post-inflammatory canalicular obstruction. Of 177 children without canalicular pathology, 171 (96%) were relieved of symptoms with one operation, without canalicular intubation. Of 81 cases with canalicular disease, 55 of 70 (79%) who underwent DCR plus canalicular intubation, and 10 of 11 who underwent DCR plus Lester-Jones tube, were substantially improved with one operation. No child required peroperative or postoperative blood transfusion. Dacryocystorhinostomy in childhood, in experienced surgical hands, is a safe procedure, achieving relief of symptoms in most cases, particularly in the absence of canalicular disease. 相似文献
3.
4.
5.
Factors influencing women to undergo screening mammography 总被引:2,自引:0,他引:2
6.
Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators 总被引:3,自引:2,他引:1 下载免费PDF全文
T. van der Molen D. S. Postma M. O. Turner B. M. Jong J. L. Malo K. Chapman R. Grossman C. S. de Graaff R. A. Riemersma M. R. Sears 《Thorax》1997,52(6):535-539
BACKGROUND: The long acting beta 2 agonist formoterol has proved to be an effective bronchodilator with a prolonged action of 12-14 hours. However, the precise role of formoterol in the maintenance treatment of asthma is still under debate. A study was performed to investigate the efficacy and safety of treatment with formoterol for six months in subjects with asthma. METHODS: In a multicentre double blind, placebo controlled, parallel group study 239 subjects with mild to moderate asthma were randomly assigned to treatment with either inhaled formoterol 24 micrograms twice daily (n = 125) or placebo (n = 114) during eight months. The study consisted of a four week run in period, a 24 week treatment period, and a four week washout period. All subjects were using regular inhaled corticosteroids (100-3200 micrograms daily) but were still needing at least five inhalations of short acting beta 2 agonist per week for symptom relief. The study was performed in 10 outpatient clinics in Canada, and five outpatient clinics and one coordinating centre for 44 Dutch general practitioners in The Netherlands. Twice daily self-reported peak expiratory flow (PEF) measurements, symptom scores, and rescue beta 2 agonist use during the last 28 treatment days compared with baseline values were used as main outcome measures. Spirometric values were measured at entry, at the start of treatment, after four, 12 and 24 weeks of treatment, and after four weeks washout. RESULTS: One hundred and twenty five subjects received formoterol 24 micrograms twice daily via Turbohaler and 114 received placebo. Baseline FEV1 was 67.1% predicted and mean bronchodilator reversibility was 26%. The mean total asthma symptom score was 3.6 (maximum possible 21). A significant decrease in symptoms in favour of formoterol (difference from placebo -0.64, 95% CI -0.04 to -1.23, p = 0.04) was observed. Compared with placebo, morning PEF increased (difference from placebo 28 l/min, 95% CI 18.3 to 37.7, p = 0.0001) and the use of short acting beta 1 agonists decreased (daytime difference from placebo -1.1 inhalation, 95% CI -1.4 to -0.7, p = 0.0001) in the formoterol group. PEF returned to baseline following discontinuation of formoterol, as did asthma symptom scores. Thirty three patients treated with formoterol and 32 treated with placebo required treatment with prednisolone during the study (58 and 55 courses, respectively). CONCLUSIONS: Adding formoterol 24 micrograms twice daily by Turbohaler to inhaled corticosteroids was effective in improving symptom scores and morning PEF, and decreasing the use of rescue beta 2 agonists. There was no apparent loss of asthma control during 24 weeks of treatment with formoterol.
相似文献
相似文献
7.
8.
Relation between respiratory symptoms, pulmonary function and peak flow variability in adults. 总被引:2,自引:0,他引:2 下载免费PDF全文
BACKGROUND--A study was carried out to determine whether subjects with respiratory symptoms are more likely to have impaired lung function or increased airway lability, and to quantify these relationships in a population of adults. METHODS--Data were collected from 511 participants (aged 20-70 years) from the Dutch part of the European Community Respiratory Health Survey (ECRHS). The symptoms analysed were: wheeze, dyspnoea > or = grade 3, nocturnal dyspnoea, cough and phlegm, and history of allergy. Lung function was measured by peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1). PEF variability was used as an index for bronchial lability. RESULTS--Both FEV1 and PEF were decreased with increasing numbers of symptoms. Subjects with one symptom had an increased risk of having an FEV1 value of < 70% (OR = 4.2) and this risk increased with an increasing number of symptoms. Subjects with three or more symptoms had an increased risk of having a PEF value of < 70%, a diurnal variation in PEF of > 10% (both OR = 4.4), and an increased risk of high between day variation (OR = 6.6). CONCLUSIONS--Subject-reported symptoms are related to impaired lung function and to increased variability of peak flow. 相似文献
9.
10.
Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. 总被引:2,自引:1,他引:1 下载免费PDF全文
BACKGROUND--Despite effective treatments, the morbidity and mortality of obstructive airways disease (asthma and COPD) remains high. Home monitoring of peak expiratory flow (PEF) is increasingly being advocated as an aid to better management of obstructive airways disease. The few available studies describing effects of treatment on the level and variation of PEF have involved relatively small numbers of subjects and did not use control groups. METHODS--Patients aged 18-60 years were selected with PC20 < or = 8 mg/ml and FEV1 < 95% confidence interval of predicted normal. They were randomised to receive, in addition to a beta 2 agonist, either an inhaled corticosteroid (BA+CS), an anticholinergic (BA+AC), or a placebo (BA+PL). One hundred and forty one of these subjects with moderately severe obstructive airways disease completed seven periods of two weeks of morning and afternoon PEF measurements at home during 18 months of blind follow up. RESULTS--Improvements in PEF occurred within the first three months of treatment with BA+CS and was subsequently maintained: the mean (SE) increase in morning PEF was 51 (8) l/min in the BA+CS group compared with no change in the other two groups. Similarly, afternoon PEF increased by 22 (7) l/min. Diurnal variation in PEF (amplitude %mean) decreased from 18.0% to 10.2% in the first three months of treatment with BA+CS. Within-subject relations between changes in diurnal variation in PEF and changes in PC20 were found to be predominantly negative (median rho-0.40) but with a large scatter. Relations between diurnal variation in PEF and changes in symptom scores, FEV1, and bronchodilator response were even weaker. CONCLUSIONS--In patients with moderately severe obstructive airways disease, PEF rates and variation are greatly improved by inhaled corticosteroids. Since the relation of diurnal PEF variation with PC20, symptoms, FEV1, and bronchodilator response were all weak, these markers of disease severity may all provide different information on the actual disease state. PEF measurements should be used in addition to the other markers but not instead of them. 相似文献